In this phase I trial of CD19-BBz (86) CAR T-cell therapy, 26 patients with refractory B-cell lymphoma were enrolled and 25 patients received the infusion, in which 1 failed the trial because of an inability to manufacture a sufficient amount of CAR T cells. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.